Anita Phancao
Advanced Heart Failure and Transplant Cardiology · Tucson, AZNPI 1396932299
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Abbott accounts for 94.1% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $11,311 and has fallen 98.8% since, to $140 in 2025.
Across 171 payments — averaging $180.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$29K
- Abiomed$318
- Corcym Inc$276
- Akcea Therapeutics, Inc.$249
- Novartis$215
- Dilon Technologies, Inc.$179
- plus $595 from 7 others
Across 17 payments — averaging $4199.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$71K
What the payments were for
- Consulting fees$17,90358%
- Speaking & faculty fees$4,00013%
- Travel & lodging$2,8719%
- Food & beverage$6,10920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 115 | $29,053 |
| Abiomed | 3 | $318 |
| Corcym Inc | 2 | $276 |
| Akcea Therapeutics, Inc. | 8 | $249 |
| Novartis | 31 | $215 |
| Dilon Technologies, Inc. | 1 | $179 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $142 |
| Medtronic | 3 | $126 |
| Actelion Pharmaceuticals US, Inc. | 1 | $108 |
| Pfizer | 1 | $99 |
| Sanofi | 1 | $92 |
| AstraZeneca | 1 | $16 |
| Boston Scientific | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate$10,478
- FreeStyle Libre Pro$9,103
- CARDIOMEMS$4,887
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,600
- Impella$280
- Perceval$276
- HemoBlast Bellows$179
- CardioMEMS HF System$159
- HeartMate 3 Left Ventricular Assist Device$136
- SUPERA$114
- UPTRAVI$108
- OPSUMIT$108
- TEGSEDI$108
How this compares
Too few advanced heart failure and transplant cardiology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $8,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $16 | $8,59411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Tucson
- Carl TongTucson$346
- Sharon PowellTucson$289
- David SteidleyPhoenix$57K
- Radha GopalanPhoenix$32K
- Geoffrey JaoScottsdale$21K
- Andrew BosharaPhoenix$14K
- Suresh YerraPhoenix$1K
- Anantharam KalyaPhoenix$1K
- Wassim AssaadScottsdale$313
- Katie MurphyScottsdale$305
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.